

S 373

Fair Prescription Drug Competition Act

Congress: 112 (2011–2013, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Feb 16, 2011

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Feb 16, 2011)

Official Text: <https://www.congress.gov/bill/112th-congress/senate-bill/373>

Sponsor

Name: Sen. Rockefeller, John D., IV [D-WV]

Party: Democratic • **State:** WV • **Chamber:** Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Inouye, Daniel K. [D-HI]	D · HI		Feb 16, 2011
Sen. Leahy, Patrick J. [D-VT]	D · VT		Feb 16, 2011
Sen. Schumer, Charles E. [D-NY]	D · NY		Feb 16, 2011
Sen. Shaheen, Jeanne [D-NH]	D · NH		Feb 16, 2011
Sen. Stabenow, Debbie [D-MI]	D · MI		Feb 16, 2011

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Feb 16, 2011

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
112 HR 741	Related bill	Feb 28, 2011: Referred to the Subcommittee on Health.

Summary (as of Feb 16, 2011)

Fair Prescription Drug Competition Act - Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the 180-day exclusivity period granted to the generic manufacturer.

Actions Timeline

- **Feb 16, 2011:** Introduced in Senate
- **Feb 16, 2011:** Sponsor introductory remarks on measure. (CR S797)
- **Feb 16, 2011:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.